Seeking Alpha

Teva launches generic Adenoscan in U.S.

  • Teva (TEVA) announces the U.S. launch of generic Adenoscan, the arrhythmias treatment marketed by Astellas Pharma (ALPMF.PK, ALPMY.PK).
  • TEVA enjoys 180 days of market exclusivity by virtue of being first to file.
  • Adenoscan has annual U.S. sales of around $65M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector